- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01913704
Pilot Study Comparing NatroxTM Topical Oxygen Therapy to A Placebo in the Management of Non-Healing Leg Ulcers
A Randomised Controlled Double Blind Pilot Study Comparing NatroxTM Topical Oxygen Therapy to A Placebo in the Management of Non-Healing Leg Ulcers in Conjunction With Standard Best Practice
Study Overview
Status
Intervention / Treatment
Detailed Description
Study Type
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
-
Prague, Czechia, 147 00
- Fakultni Nemocnice Kralovske Vinohrady, Clinical of Surgery
-
Prague, Czechia
- Fakultni Nemocnice Kralovkse Vinohrady, Clinic of Dermatology
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patients with superficial venous and mixed aetiology leg ulcers on a flat plane in surface area between 4-50cm2
- Patients with diabetes may be included providing they have good metabolic control
- Patients who understand the trial, agree to adhere to the treatment and are able to give consent
- Patients who can be followed by the same investigating team for the whole period of their participation in the study
Exclusion Criteria:
- Patients who present with wounds which are clinically infected and require antimicrobial therapy. Patients who have been treated for a wound infection with antimicrobial therapy (systematically or topically) may be included providing the wound is no longer assessed as infected and there is a two week wash-out period after the last treatment before the patient is reassessed against the inclusion and exclusion criteria
- Patients with a known sensitivity to any of the components of the evaluation device
- Patients with known or suspected malignancy in the wound or surrounding tissue
- Patients whose wounds show a percentage decrease in surface area of >25% during the two week screening period
- Patients who do not have the physical or mental capacity, or a significant other with the ability to change the NatroxTM battery pack on a daily basis
- Patients who present with more than 10% of the wound surface area covered in hard eschar
- Patients who are actively treated with immunosuppressive or cortico-steroidal medication
- Patients who are participating in another clinical trial
- Patients with a known history or poor compliance with medical treatment
- Patients who have been in this trial previously and have withdrawn
- Patients who are unable to understand the aims of the trial and do not give informed consent
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo device
The placebo comparator is a placebo version of the active device which is a system to deliver oxygen from an oxygen generator topically to the wound bed via a proprietary device. The device will be applied to the wound and attached to the placebo oxygen generator and the generator switched on at the time of enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks. |
The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device. The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks.
Other Names:
|
Active Comparator: NatroxTM Device
A system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device. The NatroxTM oxygen delivery device will be applied to the wound and attached to the NatroxTM oxygen generator which will be switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The device will be removed and reapplied at each dressing change for a treatment period of 6 weeks. |
The NatroxTM device is a system to deliver oxygen from an oxygen generator topically to the wound via a proprietary device. The NatroxTM ODS oxygen delivery device will be applied to the wound and attached to the oxygen generator and switched on at the time of first dressing application at enrolment. Secondary dressings will then be applied. The oxygen delivery device will be removed and reapplied at each dressing change for a treatment period of 6 weeks.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Effectiveness of the NatroxTM Topical Oxygen Device
Time Frame: Baseline at week 0 and then at 6 and 12 weeks
|
Effectiveness of the NatroxTM Topical Oxygen Device will be established vs. Placebo in patients with non-healing leg ulceration in conjunction with best practice.
Effectiveness will measured by the absolute and relative change in wound surface area as measured by digital photography and wound-mapping software.
|
Baseline at week 0 and then at 6 and 12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change in the wound pain over the study duration
Time Frame: Baseline at week 0, and then each weekly dressing change, 8 weeks and 12 weeks
|
Measured using a validated Visual Analogue Scale ranging from 0 to 10
|
Baseline at week 0, and then each weekly dressing change, 8 weeks and 12 weeks
|
Patient comfort with the device at dressing change
Time Frame: first removal of device and then on subsequent weekly changes
|
Patient will be recorded on each visit with the dressing applied and will be recorded as a yes/no to comfort experienced by the patients
|
first removal of device and then on subsequent weekly changes
|
Patient acceptability of the device during wear
Time Frame: Each weekly dressing change until week 6
|
Patient questioned as to ability to mobilise, comfort of dressing and device and possible disturbance of sleep patterns, answers recorded as yes/no
|
Each weekly dressing change until week 6
|
Statistical information from which to power a future large multi-centre randomised trial
Time Frame: Study End at week 12
|
Statistical information on use of Natrox device and effectiveness on patients.
Wound surface area will be measured in square centimetres as defined by wound mapping software.
The wound surface area reduction between six weeks and baseline will then be calculated.
Wound surface area will be measured at weekly intervals for the 6 weeks of active treatment and then at weeks 8 and 12 for follow up.
The primary analysis will be an intent-to-treat analysis.
A two-sided significance level of 0.05 will be used for all analyses.
A general linear model taking into account the treatment groups and centres (surgical and dermatology clinics) as fixed effects and a baseline wound surface area as a covariate will be used to test the null hypothesis of similar effects in surface area reduction between treatment groups.
|
Study End at week 12
|
Efficiency of Exudate transportation through the device to the secondary dressing
Time Frame: weekly up to week 6 (end of natrox treatment period)
|
Measured by the frequency of changes of the secondary dressing and by recording the incidence of maceration.
|
weekly up to week 6 (end of natrox treatment period)
|
Improvement in the wound bed during treatment with Natrox and Oxygen Delivery System (ODS)
Time Frame: Baseline at week zero, weekly and end of treatment at week 6
|
Measured by visual assessment weekly by the Investigators
|
Baseline at week zero, weekly and end of treatment at week 6
|
Reliability of the protocol
Time Frame: Study end follow up at week 12
|
The reliability of the protocol will be determined by ability to implement it in the clinical setting effectively and the accuracy of the outcomes delivered from the study
|
Study end follow up at week 12
|
Monitor the safety of the device in use
Time Frame: Study treatment end at week 6 and then until follow up at 12 weeks
|
Measured by recording the incidence and severity of adverse events as reported.
|
Study treatment end at week 6 and then until follow up at 12 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: R Gurlich, Professor, Fakultni Nemocnice Kralovske Vinohrady Prague
Study record dates
Study Major Dates
Study Start
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- WMC16/CZ/12
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Skin Ulcer Venous Stasis Chronic
-
RHEACELL GmbH & Co. KGFGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & ServicesCompleted
-
RHEACELL GmbH & Co. KGFGK Clinical Research GmbH; Ticeba GmbH; Granzer Regulatory Consulting & ServicesTerminatedSkin Ulcer Venous Stasis ChronicGermany
-
RHEACELL GmbH & Co. KGFGK Clinical Research GmbHRecruitingSkin Ulcer Venous Stasis ChronicGermany
-
PolarityTEProfessional Education and Research InstituteCompletedVenous Leg Ulcer | Venous Stasis | Venous Stasis UlcerUnited States
-
ACR Biologics, LLCTerminatedPressure Ulcer | Skin Ulcer Venous Stasis Chronic | Foot Ulcer ChronicUnited States
-
Erchonia CorporationTerminatedVenous Stasis UlcerUnited States, France
-
West Penn Allegheny Health SystemThe Cleveland Clinic; Tactile Systems Technology, Inc.Terminated
-
HealthpointTerminatedUlcer | Venous Ulcer | Venous Stasis UlcerGermany, Poland, Belgium, Czech Republic, Hungary
-
Tactile MedicalCompletedVenous Insufficiency | Venous Leg Ulcer | Chronic Venous Insufficiency | Venous Ulcer | Venous Stasis UlcerUnited States
-
Merakris TherapeuticsUS Department of Veterans AffairsRecruitingVenous Leg Ulcer | Venous Stasis UlcerUnited States
Clinical Trials on NatroxTM Device
-
Facet TechnologiesLifeScanCompletedDiabetesUnited States
-
Karolinska InstitutetUnknownDegenerative Disc Disease | Discogenic Low Back PainSweden
-
AOTI Ltd.UnknownDiabetic Foot UlcerUnited Kingdom, United States, Germany, France, Luxembourg
-
International Agency for Research on CancerUniversity of North Carolina Global Project Zambia; Liger Medical LlcCompleted
-
Cala Health, Inc.Not yet recruiting
-
Universitair Ziekenhuis BrusselTerminated
-
University of BernDCB Research AG; Insel Gruppe AG, University Hospital BernActive, not recruitingGlucose Metabolism Disorders | Diabetes Mellitus | Endocrine System Diseases | Metabolic DiseaseSwitzerland
-
Kasey PhiferThe National Centre for ElectroMagnetic Therapies CICCompletedUnspecified Trauma- and Stressor-Related DisorderUnited Kingdom
-
Neurolief Ltd.Completed
-
Icahn School of Medicine at Mount SinaiTivic Health SystemsRecruiting